Infectious diseases MD (Geneva University Hospital, Switzerland), editor-in-chief at CMI Communications, ESCMID's open-access journal, co-host of Communicable, CMI Comms/ESCMID podcast.
#IDSky #MedSky #AMR #UTI
Angela Huttner
Loading...
#Geneva is preparing for the #G7 meeting next week. (Riots expected.) I have never seen the city quite like this.
Angela Huttner
🎙️ Just published Communicable E55: Bonus episode – Bundibugyo Ebolavirus outbreak
Hosted by Angela Huttner and Anne-Grete Märtson with invited guests Daniel Bausch and Martin Grobusch 🌟
Listen on #Communicable: https://share.transistor.fm/s/8750e095
CMI Communications
Great paper for all the cephalexin/cefadroxil users out there! #IDSky
REMAP-CAP domain on oseltamivir vs no-antiviral for patients admitted at ICU with influenza is stopped due to potential harm!
90d mortality:
Oseltamivir=19.4% (62/319)
No antiviral=13.7% (17/124)
Last word for oseltamvir?
What’s the rationale for harm? #IDSky
www.remapcap.org/oseltamivir-...
💊 Stay up to date on antibiotic therapy and antimicrobial stewardship in the face of rising AMR. This onsite course explores resistance epidemiology, appropriate antimicrobial use, and strategies to strengthen stewardship programmes.
💡 Sign up today! https://ow.ly/Yz7y50Z7Aqs
#IDSky #clinmicro
📣 If you have questions about fosfomycin, we have answers!
Excellent review article by Tiffany Wu, Kalpana Gupta, @erinmccreary.bsky.social, Sarah Turbett & Jacob Lazarus on oral #fosfomycin & how to use it.
#IDSky #clinmicro #UTISky #Medsky #Pharmsky
www.cmi-comms.org/article/S295...
📣 New #Communicable drops Monday, 15 June!
Join hosts Josh Davis & Emily McDonald with guests Roger Lewis & Ian Marschner as they demystify Bayesian and frequentist statistical approaches in clinical trials, exploring key differences, common misconceptions, and surprising similarities. 🎙️
#IDSky
While imported Ebola disease cases in Europe are expected to be 𝗩𝗘𝗥𝗬 𝗥𝗔𝗥𝗘, healthcare professionals need the right information to recognise & safely manage suspected cases.
---
We have published a set of supporting resources for healthcare & public health professionals.
🧵⬇️
bit.ly/ECDCEbolaDRC
A great episode to learn more about the current Ebola outbreak, if nothing else but to learn how to pronounce Bundibugyo
#IDSky #IDEpi
Oral fosfomycin is a guideline-recommended first-line treatment for uncomplicated
cystitis. However, fosfomycin has demonstrated lower clinical and/or microbiological
cure rates compared with other an...
I had the honour to work with @glsaravanos.bsky.social and others on a systematic review exploring #RSV transmission in closed settings with children
We found an increased risk, but overall the evidence is limited - we need more well designed studies, esp. in childcare
#IDEpi #IDSky #EpiSky
CMI Communications
CMI Communications
José Molina
Ben Ereshefsky, PharmD
On 17 May 2026, the World Health Organization (WHO) declared the Ebola virus disease outbreak caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda a Public Health Emerge...
Background Respiratory syncytial virus (RSV) is a leading cause of severe respiratory infections in children and is predominantly acquired and spread in community settings such as households and ear...
🎙️ Just published Communicable E55: Bonus episode – Bundibugyo Ebolavirus outbreak
Hosted by Angela Huttner and Anne-Grete Märtson with invited guests Daniel Bausch and Martin Grobusch 🌟
Listen on #Communicable: https://share.transistor.fm/s/8750e095
European Centre for Disease Prevention and Control
Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs?
We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social
accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
Anita Williams
Anita Williams
Optimal cephalexin and cefadroxil dosing for skin and soft tissue infections (SSTIs) is unclear. We summarize clinical and pharmacokinetic/pharmacodynamic (PK/PD) data that compare dosing strategies ...
